M E Witt
Overview
Explore the profile of M E Witt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Das L, Karrison T, Witt M, Muller C, Stenson K, Blair E, et al.
Ann Oncol
. 2014 Nov;
26(1):198-205.
PMID: 25361984
Background: Human papillomavirus (HPV) has emerged as a causative agent and positive prognostic factor for oropharyngeal (OP) head and neck squamous cell cancer (HNSCC). This prompts inquiry into whether therapy...
2.
Seiwert T, Darga T, Haraf D, Blair E, Stenson K, Cohen E, et al.
Ann Oncol
. 2012 Oct;
24(3):769-76.
PMID: 23104721
Background: AdGV.EGR.TNF.11D (TNFerade™ Biologic) is a replication-deficient adenoviral vector expressing human tumor necrosis factor alpha (TNF-α) under the control of the chemoradiation-inducible EGR-1 promoter. TNF-α has been shown to function...
3.
Golden D, Rudra S, Witt M, Nwizu T, Cohen E, Blair E, et al.
Oral Oncol
. 2012 Oct;
49(3):277-82.
PMID: 23102863
Purpose: Current standard therapy for nasopharyngeal carcinoma (NPC) is concurrent chemoradiation based on randomized data. However, limited randomized data exist to support the addition of induction chemotherapy (ICT). Methods: 58...
4.
Villaflor V, Haraf D, Salama J, Kocherginsky M, Langerman A, Gomez-Abuin G, et al.
Ann Oncol
. 2011 Mar;
22(11):2501-2507.
PMID: 21385883
Background: Concurrent chemoreirradiation therapy (CRRT) offers a therapeutic option for patients with locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN). We hypothesized that response to induction chemotherapy...
5.
Salama J, Haraf D, Stenson K, Blair E, Witt M, Williams R, et al.
Ann Oncol
. 2011 Feb;
22(10):2304-9.
PMID: 21330337
Introduction: We conducted a randomized phase II study to evaluate the impact of adding bevacizumab (B) to 5-fluorouracil (5-FU), hydroxyurea (HU), and radiotherapy (FHX) for intermediate-stage and select T4 head...
6.
Salama J, Stenson K, Kistner E, Mittal B, Argiris A, Witt M, et al.
Ann Oncol
. 2008 Jun;
19(10):1787-94.
PMID: 18539617
Background: We hypothesized induction chemotherapy (IndCT) would improve distant control (DC) without compromising locoregional control (LRC) for locoregionally advanced head and neck cancer patients. Additionally, we systematically lowered radiotherapy (RT)...
7.
Knab B, Salama J, Solanki A, Stenson K, Cohen E, Witt M, et al.
Ann Oncol
. 2008 May;
19(9):1650-4.
PMID: 18467314
Background: Randomized trials established chemoradiotherapy as standard treatment for advanced laryngeal cancer. Patients with large-volume T4 disease (LVT4) were excluded from these trials. The purpose of this study was to...
8.
Oh J, Vokes E, Kies M, Mittal B, Witt M, Weichselbaum R, et al.
Ann Oncol
. 2003 Mar;
14(4):564-9.
PMID: 12649102
Background: Since 1990, we have treated patients with advanced nasopharyngeal cancer with induction chemotherapy and concomitant chemoradiotherapy. We herein report the results of our experience. Patients And Methods: From 1990...
9.
Hsi R, Witt M, Jesse M, Yakshaw A, Delay A, Landes J
Cancer Pract
. 2002 Mar;
8(6):264-7.
PMID: 11898142
No abstract available.
10.
Mantz C, Vokes E, Kies M, Mittal B, Witt M, List M, et al.
Ann Oncol
. 2001 May;
12(3):343-7.
PMID: 11332146
Purpose: To determine overall survival, progression-free survival, rate of voice preservation, and patterns of failure in locoregionally advanced laryngeal cancer treated with induction chemotherapy with or without surgery followed by...